Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Pharmacy Chain 36.6 reported for 2023 by RAS

3/11/24 APTK

Yandex Cloud neural network has learned to recognize emotions

3/11/24 YNDX

Transneft to increase oil shipments to East

3/11/24 TRNFP

Polymetal completed the sale of its Russian business

3/11/24 POLY

Tatneft agrees with SOCAR on cooperation in petrochemistry

3/8/24 TATN

Yandex shareholders approve restructuring

3/7/24 YNDX

Positive Technologies disclosed the parameters of additional share issue

3/7/24 POSI

CherMK's blast furnace was not damaged

3/7/24 CHMF

Rostelecom completed construction of the 2nd stage of the TEA NEXT FOCL line

3/7/24 RTKM

Kamaz will supply Moscow with 1.5 thousand electric buses

3/7/24 KMAZ